Skip to main content

Advertisement

Table 4 Adverse events

From: Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry

Type of Adverse Events Clinical Adverse Events*
N = 103
n (%)
Laboratory Adverse Events**
N = 103
n (%)
Any adverse events 4 (3.9) 8 (7.8)
Serious adverse events 3 (2.9) 1 (0.9)
Serious adverse events leading to discontinuation 2 (1.9) 1 (0.9)
  1. * Clinical adverse events include: bronchopneumonia; skin reaction; respiratory failure; and abdominal pain
  2. **Laboratory adverse events include: increase in aspartate aminotransferase, alanine aminotransferase, blood alkaline phosphatase, blood bilirubin, gamma glutamyltransferase; leukopenia; hyperbilirubinemia; and hypokalemia.